High Tide Inc. · HITI
$48M
$54M
$72M
$81M
$95M
$108M
$118M
$118M
$124M
$127M
$128M
$124M
$132M
$138M
$142M
$138M
$150M
$164M
$178M
$179M
20-quarter listed-company comparison
Pharmaceutical Retailers Stocks
Pharmaceutical Retailers: High Tide Inc. owns the largest revenue base AND the fastest current growth.
01 · sector relative strength, before individual stocks
Is Pharmaceutical Retailers outperforming S&P 500?
Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 0.2%. 0 of 1 covered company currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. High Tide Inc. is the strongest against the sector itself at 0%.
+0.2%Sector vs S&P 500 · 13 weeks
-41.9%Sector vs S&P 500 · 52 weeks
0/1Stocks leading S&P 500
0/1Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over 52 weeks and 0.2% over 13 weeks. 0 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. High Tide Inc. leads with revenue of $671 million, based on 1 of 1 comparable companies through Jun 2026.
Companies
1
complete canonical membership
Combined market value
$216M
High Tide Inc.
Revenue growing
1/1
positive TTM year-on-year growth
Beating S&P 500
0/1
positive Mansfield relative strength
Comparing 1 of 1
02 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
High Tide Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 57.7% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1High Tide Inc.HITI | 44.3/100Thin evidence · provisional58% evidence | TURNING | 23.8/35 Revenue 22% · PAT — · OPM change 2.4 pp 71% evidence | 3.0/25 ROCE 3.3% · OPM 4.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.5/20 RS sector 0% · RS bench -15.7% · 1Y -31.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 23.8 + 3 + 10 + 7.5 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
03 · what price has already done
Market action
High Tide Inc. has the strongest one-year price move in Pharmaceutical Retailers at -31.4%. It also leads on Mansfield relative strength against the S&P 500 at -15.7%. 0 of 1 covered company are above zero on that measure. Every line covers 314 weekly closes through 2026-08-20.
Price and relative strength
Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Pharmaceutical Retailers itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
04 · compare level, then change
Revenue Scale & Growth Durability
High Tide Inc. is the only Pharmaceutical Retailers company on this page, with Revenue of $671 million. The same company also holds the highest Revenue growth, at 22%. That is the only usable Revenue reading on this page, current through Jun 2026. Its Revenue series carries 20 reported observations across the 20-quarter window.
What the numbers say: High Tide Inc. is the scale leader at $671 million, High Tide Inc.'s growth is 22% from a $671 million base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderHigh Tide Inc. · $671 million
GapNot enough peers
Persistence8/8 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: High Tide Inc. is the scale benchmark; High Tide Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: High Tide Inc.'s growth falls below High Tide Inc.'s for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
1/1 level · 1/1 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| High Tide Inc. HITI | $179M | 30% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Revenue growth · reported quarter history
High Tide Inc. · HITI
—
—
—
—
98%
100%
64%
46%
31%
18%
8.5%
5.1%
6.5%
8.7%
11%
11%
14%
19%
25%
30%
05 · compare level, then change
Operating Economics & Margin Trend
High Tide Inc. is the only Pharmaceutical Retailers company on this page, with OPM of 4.1%. The same company also holds the highest Margin change, at +2.4 percentage points. That is the only usable OPM reading on this page, current through Jun 2026. Its OPM series carries 20 reported observations across the 20-quarter window.
What the numbers say: High Tide Inc. leads both opm at 4.1% and margin change at +2.4 percentage points.
LeaderHigh Tide Inc. · 4.1%
GapNot enough peers
Persistence6/8 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| High Tide Inc. HITI | 4.1% | +2.4 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
High Tide Inc. · HITI
-14%
-4.2%
-7.3%
-8.3%
-4.1%
-49%
-2.5%
-1.3%
0.5%
0.9%
3.1%
2.5%
3.4%
2.7%
1.1%
1.7%
3.6%
3.5%
1.9%
4.1%
Margin change · reported quarter history
High Tide Inc. · HITI
—
—
—
—
+10.1 pp
−44.7 pp
+4.8 pp
+7.0 pp
+4.6 pp
+49.8 pp
+5.6 pp
+3.8 pp
+2.9 pp
+1.8 pp
−2.0 pp
−0.8 pp
+0.2 pp
+0.8 pp
+0.8 pp
+2.4 pp
06 · compare level, then change
Profit Scale & Acceleration
High Tide Inc. is the only Pharmaceutical Retailers company on this page, with Net profit of $46 million net cash. That is the only usable Net profit reading on this page, current through Jun 2026. Its Net profit series carries 20 reported observations across the 20-quarter window.
What the numbers say: High Tide Inc. leads net profit at $46 million net cash; the second comparison lacks enough current evidence.
LeaderHigh Tide Inc. · $46 million net cash
GapNot enough peers
Persistence0/1 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
—Not enough comparable data—
Net profit · company comparison
1/1 level · 0/1 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| High Tide Inc. HITI | $0M | 0.0% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
High Tide Inc. · HITI
$-2M
$-4M
$-7M
$-8M
$-3M
$-53M
$-4M
$-2M
$-4M
$-32M
$0M
$0M
$1M
$-5M
$-3M
$-3M
$1M
$-47M
$0M
$0M
Profit growth · reported quarter history
High Tide Inc. · HITI
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.0%
—
—
—
07 · compare level, then change
Return On Capital Employed
High Tide Inc. is the only Pharmaceutical Retailers company on this page, with ROCE of 3.3%. The same company also holds the highest ROCE change, at +2 percentage points. That is the only usable ROCE reading on this page, current through Jun 2026. Its ROCE series carries 19 reported observations across the 20-quarter window.
What the numbers say: High Tide Inc. leads ROCE at 3.3%. High Tide Inc. has the strongest latest improvement at +2 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderHigh Tide Inc. · 3.3%
GapNot enough peers
Persistence6/8 recent comparable periods
Coverage1/1 companies · 19 observations
Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| High Tide Inc. HITI | 3.3% | +2.0 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
High Tide Inc. · HITI
—
-1.8%
-2.9%
-3.3%
-1.7%
-25%
-1.3%
-0.7%
0.3%
0.6%
2.1%
1.6%
2.3%
2.1%
0.9%
1.3%
2.8%
2.6%
1.6%
3.3%
ROCE change · reported quarter history
High Tide Inc. · HITI
—
—
—
—
—
−23.4 pp
+1.6 pp
+2.6 pp
+2.0 pp
+25.8 pp
+3.4 pp
+2.3 pp
+2.0 pp
+1.5 pp
−1.2 pp
−0.3 pp
+0.5 pp
+0.5 pp
+0.7 pp
+2.0 pp
08 · not available
Valuation Against Growth & Quality
No company in this Pharmaceutical Retailers comparison reports valuation on a comparable basis, so there is nothing to rank here — 0 of 1 company has a usable current reading. The section is shown rather than removed so an unavailable metric is not mistaken for one that was quietly left out. Filings were read through Jun 2026.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
09 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Pharmaceutical Retailers comparison names 5 specific ways its own evidence can mislead, all listed below. The one company here reports on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- Thin comparisons: Valuation have fewer than three usable current readings.
10 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 1 Pharmaceutical Retailers company, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-20. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-20 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
11 · questions investors ask, short speakable answers
Pharmaceutical Retailers company comparison FAQs
These 19 answers restate the Pharmaceutical Retailers comparison above in question form. Every one is computed from the same 1 company and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-20. Nothing here is estimated, and none of it is a recommendation.
Is the Pharmaceutical Retailers sector outperforming S&P 500?
Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over 52 weeks and 0.2% over 13 weeks. 0 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself.
Which Pharmaceutical Retailers company is largest by revenue?
High Tide Inc. leads with revenue of $671 million, based on 1 of 1 comparable companies through Jun 2026.
Which Pharmaceutical Retailers company is growing fastest?
High Tide Inc. has the fastest current revenue growth at 22%, across 1 of 1 comparable companies.
Which Pharmaceutical Retailers company has the strongest 4-Factor Sector Score?
High Tide Inc. ranks first at 44.3/100 with 57.7% evidence confidence. The score prioritizes research; it is not a buy recommendation.
How much history does this Pharmaceutical Retailers comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Which Pharmaceutical Retailers company is the biggest?
High Tide Inc. is the largest, with trailing-twelve-month revenue of $671 million. That covers 1 of 1 companies with comparable reporting through Jun 2026.
Which Pharmaceutical Retailers company has the best profit margins?
High Tide Inc. has the highest operating margin at 4.1%, from 1 of 1 comparable companies. High Tide Inc. shows the biggest recent improvement, at +2.4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharmaceutical Retailers company makes the most profit?
High Tide Inc. earns the most, at $46 million of trailing-twelve-month net profit, from 1 of 1 comparable companies.
Which Pharmaceutical Retailers company earns the highest return on capital?
High Tide Inc. leads on return on capital employed at 3.3%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Is the Pharmaceutical Retailers sector beating the market?
Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over the last 52 weeks and 0.2% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 0 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Pharmaceutical Retailers stock has the strongest price momentum?
High Tide Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharmaceutical Retailers company scores highest for research priority?
High Tide Inc. scores 44.3 out of 100 with 57.7% evidence confidence, from 23.8 points on growth and earnings, 3 on capital efficiency, 10 on valuation and 7.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharmaceutical Retailers companies does this comparison cover, and over what period?
It compares 1 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharmaceutical Retailers sector?
The 1 Pharmaceutical Retailers companies on this page carry $216 million of combined market value. High Tide Inc. is the largest at $216 million, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.
How is the Pharmaceutical Retailers sector performing?
0 of the 1 covered Pharmaceutical Retailers companies are beating S&P 500 on Mansfield relative strength. The sector itself is 41.9% behind S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.
How many Pharmaceutical Retailers stocks are listed in the US?
This comparison covers 1 listed Pharmaceutical Retailers companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.
Not SEBI Registered !! Not Investment advice !!